Objective: In this study, the therapeutic and protective effects of montelukast against cisplatin (CP)-induced acute renal damage were investigated. Materials and Methods: Thirty-five female rats were divided into five groups as follows: (1) control, (2) montelukast (10 mg/kg daily for 10 days per-oral (p.o.), (3) CP (single dose 7 mg/kg intraperitoneally (i.p.)), (4) CP + montelukast (10 mg/kg daily for 10 days p.o., after 3 days of the injection of CP), (5) montelukast (10 mg/kg daily for 10 days p.o.) + CP (single dose 7 mg/kg i.p., after the last dose of montelukast). At the end of the experiment, malondialdehyde (MDA), a lipid peroxidation product, myeloperoxidase (MPO), and reduced glutathione (GSH) levels were determined in the renal tissue. Also, blood urea nitrogen (BUN) and creatinine (Cr) levels were assayed from the trunk blood samples. Results: CP treatment caused a significant elevation of MDA, MPO, BUN, and Cr levels when compared with the control group. Also, GSH levels were found to be reduced due to the CP treatment. Montelukast administration after CP injection ameliorated all of these parameters. Our histopathological findings (marked swelling of epithelial cells, tubular dilatation, tubular desquamation, and loss of brush border in the kidney) were consistent with the biochemical results. Conclusion: Montelukast treatment after CP injection exerted therapeutic effects against CP-induced acute kidney damage.
C1 [Beytur, Ali] Inonu Univ, Fac Med, Dept Urol, TR-44280 Malatya, Turkey.
[Kose, Evren; Sapmaz, Hilal Irmak; Dogan, Zumrut; Ekinci, Nihat] Inonu Univ, Fac Med, Dept Anat, TR-44280 Malatya, Turkey.
[Sarihan, Mehmet Ediz] Inonu Univ, Fac Med, Dept Emergency, TR-44280 Malatya, Turkey.
[Cetin, Asli; Vardi, Nigar] Inonu Univ, Fac Med, Dept Histol, TR-44280 Malatya, Turkey.
[Turkoz, Yusuf] Inonu Univ, Fac Med, Dept Biochem, TR-44280 Malatya, Turkey.